Does safety make a difference in selecting the right TNF antagonist?

Arthritis Research & Therapy
Roy M Fleischmann, David Yocum

Abstract

Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved the outcomes in patients with rheumatoid arthritis (RA). At this report, safety data were collected on approximately 271,000 patients administered infliximab (as of February 2002), 121,000 patients administered etanercept (as of December 2001), and on 2400 patients who received adalimumab in trials in connection with the regulatory approval process (approval granted December 2002 in the US and September 2003 in European Union). Infliximab and etanercept have predictable and manageable safety profiles, and preliminary data suggest that the profile of adalimumab is comparable. Safety issues involving the anti-TNF agents as a class include the risk of injection-site reactions or infusion-related reactions, infection (for example, serious, opportunistic, or tubercular), malignancy, autoimmunity, and demyelinating and neurologic disorders. Injection-site and infusion-related reactions are most often easily managed and rarely lead to discontinuation of therapy. Infections can be minimized or prevented by screening and careful monitoring and follow-up; most infections respond to appropriate medical treatment. More studies are neede...Continue Reading

References

Feb 17, 1993·Journal of the National Cancer Institute·G GridleyJ F Fraumeni
Nov 14, 1997·Immunology Today·A EiglerS Endres
Dec 22, 1999·Alimentary Pharmacology & Therapeutics·S B Hanauer
Mar 7, 2000·Lancet·F C Breedveld
Oct 31, 2000·International Journal of Cancer. Journal International Du Cancer·E ThomasG J Macfarlane
Nov 7, 2000·Journal of Pharmaceutical Sciences·S Porter
Nov 30, 2000·The New England Journal of Medicine·P E LipskyUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
Jun 9, 2001·Rheumatic Diseases Clinics of North America·E C Keystone
Dec 12, 2001·JAMA : the Journal of the American Medical Association·D S Pisetsky, E W St Clair
Oct 2, 2002·Arthritis and Rheumatism·Michele F DoranSherine E Gabriel
Jun 24, 2003·The American Journal of Gastroenterology·Adam CheifetzScott Plevy

❮ Previous
Next ❯

Citations

Mar 25, 2008·Therapeutics and Clinical Risk Management·Kim A Papp
Feb 4, 2005·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·K Greiner, J Plskova
May 19, 2010·Expert Review of Clinical Immunology·Danial E Baker
Dec 18, 2010·Expert Review of Clinical Immunology·Enrico MaggiAndrea Matucci
Mar 1, 2008·Expert Opinion on Drug Discovery·Marcus D Köller
Mar 26, 2005·Immunological Reviews·Jörg J Goronzy, Cornelia M Weyand
May 13, 2005·The British Journal of Dermatology·D HircheS A Eming
Jun 27, 2006·International Journal of Dermatology·Patricia T Ting, John Y Koo
Nov 17, 2005·Rheumatic Diseases Clinics of North America·Jeska K de Vries-BouwstraFerdinand C Breedveld
Dec 1, 2017·Ophthalmology and Therapy·Srilakshmi M SharmaKanmin Xue
Jun 15, 2006·Nature Reviews. Drug Discovery·Luke A J O'Neill
Nov 24, 2006·Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society·Linda Leff
Jan 18, 2007·Pediatric Emergency Care·Bridgette GuthrieSally L Reynolds
Oct 9, 2007·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Magdalena DziadzioClare Higgens
Jul 18, 2008·Acta Ophthalmologica·Sven SahlinAbiel Orrego
Sep 9, 2005·Medicine·Nancy F CrumMark R Wallace
Feb 4, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Neil H Shear
Jun 10, 2021·Open Access Rheumatology : Research and Reviews·Eduardo MyslerAna Lizarraga
Jun 26, 2021·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Veranika SasnovskayaAimee Chevalier
Jul 20, 2016·Pediatrics·H Dele Davies, UNKNOWN COMMITTEE ON INFECTIOUS DISEASES

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray
biopsy

Software Mentioned

ATTRACT

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Adolescent Health, Medicine and Therapeutics
Lauren Keyser McCluggage
The Journal of Rheumatology. Supplement
Edward C Keystone
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
David J HarrisonDenise Globe
© 2022 Meta ULC. All rights reserved